Severe cognitive impairment

Trefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114 for Treatment of Corneal Epithelial Defects

Retrieved on: 
Wednesday, January 18, 2023
Pharmaceutical, Optical, Health, Clinical Trials, Infection, Severe cognitive impairment, Therapy, California Pacific Medical Center, Cornea, Safety, Human, Research, Pain, Pharmaceutical industry

Trefoil Therapeutics , a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced the dosing of the first patient in its Phase 1 safety study evaluating TTHX1114 as a topical eye drop formulation designed to reduce the duration and impact of corneal epithelial defects.

Key Points: 
  • Trefoil Therapeutics , a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced the dosing of the first patient in its Phase 1 safety study evaluating TTHX1114 as a topical eye drop formulation designed to reduce the duration and impact of corneal epithelial defects.
  • Corneal epithelial defects are open “sores” in the outer layer of the cornea that develop from common infections, eye trauma and neurotrophic keratopathy.
  • “Corneal epithelial defects can develop quickly from eye trauma, bacterial or viral infections such as a herpes reactivation, or from Sjögren's syndrome, among many other causes.
  • “We are excited to take this important step to research TTHX1114 as a topical therapy,” said David Eveleth, Ph.D., President and CEO of Trefoil Therapeutics.

CXL Ophthalmics Appoints Jonathan Talamo, MD, as Chair of the Board

Retrieved on: 
Wednesday, January 18, 2023
Health, Surgery, Clinical Trials, Research, Science, Optical, Biotechnology, Johnson & Johnson Vision, Severe cognitive impairment, Chief medical informatics officer, CXL, Keratoconus, Safety, MD, Risk, Medical Affairs Bureau, Cornea, Cataract, Therapy, Patient, Inflammation, Worldwide, Pharmaceutical industry, Medical device

CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today announced that Jonathan Talamo, MD has been appointed as its new Chair of the Board of Directors.

Key Points: 
  • CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today announced that Jonathan Talamo, MD has been appointed as its new Chair of the Board of Directors.
  • Dr. Talamo has served as a Board Member for the company since 2020.
  • Dr. Talamo, an ophthalmic surgeon with over 25 years in clinical practice, is a leader in corneal disease, cataract, and refractive surgery.
  • “I am thrilled to work more closely with the CXLO Board as we develop the minimally-invasive EpiSmart cross-linking system to improve patient comfort and preserve vision,” said Dr. Talamo.

Bausch + Lomb Acquires AcuFocus, Inc.

Retrieved on: 
Tuesday, January 17, 2023
Medical Supplies, Medical Devices, Health, Surgery, General Health, Optical, Cataract, Severe cognitive impairment, Ageing, Presbyopia, Regulation of tobacco by the U.S. Food and Drug Administration, NYSE, Food, Growth, EDOF, Patient, Bausch & Lomb, Physician, Dioptre, Astigmatism, Multimedia, Telescopic sight, Pharmaceutical industry, IOL

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. (“AcuFocus”), a privately held ophthalmic medical device company, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. (“AcuFocus”), a privately held ophthalmic medical device company, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.
  • Known as the IC-8 IOL in global markets, this IOL is available in select markets across Europe, as well as in Australia, New Zealand and Singapore.
  • Some available presbyopia-correcting IOLs have complex optics that split, shift or stretch light to provide clear vision at more than one discrete focal point.
  • “With its extensive development footprint and renowned commercial expertise, we believe Bausch + Lomb is best positioned to educate physicians about the IC-8 Apthera lens, and ultimately, ensure more cataract patients have access to this new IOL.”

Having Committed to Growth in the New Year, Unicoeye Accelerates Its Online Expansion

Retrieved on: 
Friday, January 13, 2023
Severe cognitive impairment, Lens (anatomy), Social media, Criticism of the Food and Drug Administration, Eye color, Eye injury, Public health, Safety, FDA, Pharmacy, Growth, Food, Lens, Research, Cosmetics

WHIPPANY, N.J., Jan. 13, 2023 /PRNewswire/ -- Unicoeye, an online retailer of colored contact lenses, is entering the new year with the ambitious goal of accelerating its online expansion.

Key Points: 
  • WHIPPANY, N.J., Jan. 13, 2023 /PRNewswire/ -- Unicoeye, an online retailer of colored contact lenses, is entering the new year with the ambitious goal of accelerating its online expansion.
  • The company is committed to achieving growth in 2023 and is taking the necessary steps to ensure this goal is met.
  • To achieve its planned online expansion, Unicoeye has decided to start by adjusting product prices and hosting promotions.
  • "With the right approach, we are confident that we can reach our goals of online expansion and overall growth this year."

20/20 Onsite, Warby Parker & Boston Public Schools Reunite for “Vision for Boston”

Retrieved on: 
Wednesday, January 11, 2023
General Health, Philanthropy, Family, Optical, Consumer, Primary, Secondary, Teens, Education, Foundation, Children, Medical Supplies, Other Philanthropy, Health, Vision, BTU, Eye, Student, Insurance, Learning, NPS, Optometry, Irving Middle School, Glasses, Nursing, City, Knowledge, NECO, Grand Erie District School Board, New England College, Organization, Partnership, School, BPS, Patient, Retina, New England, Boston Public Schools, CASH, Chelsea High School, Life, Severe cognitive impairment, New England College of Optometry, Medicine, Tutoring, Onshore

Massachusetts state law requires all Boston Public School students in grades K0-5, 7, and 10 to receive a vision screening in school each year.

Key Points: 
  • Massachusetts state law requires all Boston Public School students in grades K0-5, 7, and 10 to receive a vision screening in school each year.
  • Warby Parker has designed a line of glasses specifically for students that are part of this program through Warby Parker’s Pupils Project initiative.
  • The Boston Public Schools (BPS), the birthplace of public education in the United States, serves nearly 55,000 pre-kindergarten through grade 12 students in 125 schools.
  • To date, Warby Parker has worked alongside its nonprofit partners to distribute more than 10 million glasses to people in need.

ITC Judge Rules Apple Violated U.S. Trade Laws by Infringing Masimo Pulse Oximeter Patent

Retrieved on: 
Wednesday, January 11, 2023
Consumer Electronics, Medical Devices, Health, Technology, Health Technology, Wearables, Mobile Technology, Severe cognitive impairment, COVID, MASI, United States International Trade Commission, Administrative law, Heart, Apple Watch, Tariff Act, AAPL, Pulse, Apple Inc., Apple Watch Series 6, Patient, Apple, ALJ, USITC, Medical imaging, D.C, Masimo

A United States Administrative Law Judge in Washington, D.C. ruled that Apple Inc. (Nasdaq: AAPL) violated Section 337 of the Tariff Act of 1930 as amended, by importing and selling within the United States certain Apple Watches with light-based pulse oximetry functionality and components, which infringe one of Masimo’s (Nasdaq: MASI) pulse oximeter patents.

Key Points: 
  • A United States Administrative Law Judge in Washington, D.C. ruled that Apple Inc. (Nasdaq: AAPL) violated Section 337 of the Tariff Act of 1930 as amended, by importing and selling within the United States certain Apple Watches with light-based pulse oximetry functionality and components, which infringe one of Masimo’s (Nasdaq: MASI) pulse oximeter patents.
  • Apple first released its pulse oximeter sensor with the Apple Watch Series 6 in 2020 and continues to use it in the current Apple Watches.
  • The United States International Trade Commission (USITC) will now consider whether to implement an import ban on these Apple Watches.
  • “We are happy that the ALJ recognized Apple’s infringement of Masimo’s pulse oximetry technology and took this critical first step toward accountability,” said Joe Kiani, CEO of Masimo.

Diabetic Macular Edema Treatment Global Market Report 2022: Featuring Allergan, Genetech, Novartis, Regeneron Pharmaceuticals & More - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
General Health, Health, Optical, American Academy of Ophthalmology, Severe cognitive impairment, Novartis, Triamcinolone, Bevacizumab, Blood, Alimera Sciences, Safety, Macular edema, Xanthophyll, Fluocinolone acetonide, Conbercept, Pharmacotherapy, Bausch, Diabetic retinopathy, Dexamethasone, World Health Organization, Patient, Diabetes, Retina, American Academy, VEGF, Incidence, Allergan, Inc., Pharmaceutical industry, Ranibizumab, Ophthalmology

The "Diabetic Macular Edema Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetic Macular Edema Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The therapy segment for diabetic macular edema treatment mainly comprises drugs and surgery.
  • The competitive landscape is an assessment tool that highlights the performance of the fundamental players currently engaged in the diabetic macular edema treatment market.
  • It is prevalent in two forms: focal diabetic macular edema, which employs surgical treatment options, and diffuse macular edema, which is treated with drug therapy.

Global Safety Eyewear Market Report 2022: Growing Environmental Pollution Boosting Need For Protective Eyewear - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Mining, Minerals, Military, Other Construction & Property, Residential Building & Real Estate, Natural Resources, Machinery, Commercial Building & Real Estate, Other Manufacturing, Machine Tools, Metalworking & Metallurgy, Construction & Property, Health, Chemicals, Plastics, Automotive Manufacturing, Aerospace, Manufacturing, Defense, Optical, Cataract, Severe cognitive impairment, Occupational safety and health, Bureau, Occupational Safety and Health Administration, Kimberly-Clark, Conjunctivitis, Bureau of Labor Statistics, Safety, Risk, Approximation error, Health, Air pollution, 3M, Honeywell, Smoke, Lead, Sulfur dioxide, Particulates, Research, Nitrogen, Industrial, Eye, Carbon monoxide, Nitrogen dioxide, BLS, Employment, OSHA, Dietary supplement, Personal protective equipment, Mining

The Global Safety Eyewear Market size is expected to reach $4.8 billion by 2028, rising at a market growth of 4.5% CAGR during the forecast period.

Key Points: 
  • The Global Safety Eyewear Market size is expected to reach $4.8 billion by 2028, rising at a market growth of 4.5% CAGR during the forecast period.
  • In order for workers to perform their duties completely and efficiently, safety eyewear must also guarantee that they have the proper vision.
  • The use of safety eyewear is crucial for every work, where, there is a risk or danger to the eyes.
  • On the basis of application, the safety eyewear market is fragmented into oil & gas, construction, mining, industrial manufacturing, military and others.

Pixium Vision announces peer-reviewed publications demonstrating the potential of the Next Generation PRIMA implant to restore vision at five times higher resolution than current implant

Retrieved on: 
Thursday, January 12, 2023
Diamond, Retinal degeneration, Visual impairment, PRIMA, Severe cognitive impairment, CET, Nature Communications, Stanford University, AMD, Hope, Human, Bipolar, Vance DeGeneres, Patient, Retina, Visual acuity, Journal, Neuron, Nervous system, Pixel, Mnemos EP, RATS, Electrode, Telescopic sight, Television, Medical device, Camera, Dentistry, Ophthalmology

Pixium Vision is developing the second generation of PRIMA implants in collaboration with its long-term academic partner Stanford University.

Key Points: 
  • Pixium Vision is developing the second generation of PRIMA implants in collaboration with its long-term academic partner Stanford University.
  • "Our new second generation PRIMA implant represents a huge leap forward in prosthetic vision and offers a real chance to restore sight close to natural vision in patients blinded by retinal degeneration," said Lloyd Diamond, Chief Executive Officer of Pixium Vision.
  • They are based on the design of the original PRIMA implants, which were also co-developed by Pixium Vision and Stanford University.
  • A resolution of 24mm on the retina corresponds to 5 times higher acuity than the clinical average with the current implant, promising a significant improvement of central vision for many AMD patients.

Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating NEXAGON® for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Retrieved on: 
Monday, January 9, 2023
CTI, Failure, IgG4-related ophthalmic disease, Severe cognitive impairment, Safety, FDA, Cornea, Homeostasis, Fisher, CSO, Patient, Patent, GJA1, SAN, Amber, Inflammation, ARVO, Pharmaceutical industry

Subjects meeting the eligibility criteria were randomized to receive NEXAGON high concentration, NEXAGON low concentration, or vehicle alone (control).

Key Points: 
  • Subjects meeting the eligibility criteria were randomized to receive NEXAGON high concentration, NEXAGON low concentration, or vehicle alone (control).
  • Corneal epithelial recovery (primary endpoint) was defined as corneas exhibiting complete corneal re-epithelialization within the treatment period that is maintained for at least 28 continuous days (response + durability).
  • An analysis of the data was performed once 35 patients of a planned 108 were enrolled and had completed the study.
  • Subjects, with ages ranging from 7 to 75 years, had an average baseline corneal defect area of 46.67 mm2 (4 to 176 mm2).